Cytek Biosciences Inc (CTKB) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Cytek Biosciences Inc   (NASDAQ: CTKB)

Select the Financial Report: Select the Period:


Description of Cytek Biosciences Inc's Business Segments


Cytek Biosciences Inc. is a prominent player in the life sciences sector, specifically focusing on innovative flow cytometry solutions. These solutions empower scientists and researchers to explore the intricate biology of diseases, paving the way for novel treatments and enhancements in patient care. The companys commitment to delivering high-performance flow cytometers showcases its emphasis on exceptional performance, unparalleled flexibility, and user-friendliness, all at competitive price points.

Segments:

Cytek Biosciences operates primarily within two significant customer segments in the life sciences industry: research institutions and clinical companies.

1. Research Institutions:
- This segment includes academic institutions, biotechnology firms, pharmaceutical companies, and government research organizations. Cytek’s products are tailored for researchers involved in various stages of research, including:
- Basic Research: Focusing on understanding fundamental biological processes.
- Translational Research: Aimed at translating basic research findings into practical applications, such as developing new therapies and diagnostic tools.
- Clinical Research: Involving the testing and validation of hypotheses in patient populations, seeking improve treatment protocols and patient outcomes.

2. Clinical Companies:
- In this segment, Cyteks flow cytometry solutions are utilized in clinical laboratories for:
- Diagnostic Purposes: Identifying diseases through analysis of blood and tissue samples.
- Monitoring Treatment Efficacy: Evaluating how well treatments are working in patients.
- Assessing Disease Progression: Tracking patient health over time to inform clinical decisions.

Products:

Cytek Biosciences offers a suite of advanced flow cytometer platforms, each designed to meet distinct research and clinical needs:

1. Aurora System:
- The Aurora system is renowned for its high-performance capabilities, facilitating carboxy-based multiparametric analysis.
- Key features of the Aurora include:
- Innovative Optical Design: This design enhances sensitivity and resolution, allowing for detailed data acquisition crucial for improved healthcare outcomes.
- Multiparametric Capability: Enables the simultaneous analysis of multiple parameters, providing comprehensive insights into cellular characteristics.

2. Northern Lights Series:
- The Northern Lights series includes two models: the Northern Light and the Northern Light 2L.
- This series is designed with flexibility and cost-effectiveness in mind, featuring:
- High-Throughput Capacity: Ideal for labs looking to increase their productivity while managing budgetary constraints.
- User-Friendly Interface: Simplifying operation, this design accommodates users with varying levels of expertise in flow cytometry.
- Expandable Capabilities: Researchers can adapt and expand their systems as their research needs evolve.

3. DxP Athena:
- The DxP Athena platform is specifically tailored for clinical laboratories, characterized by:
- Robust Clinical Features: Suitable for a range of clinical applications, including immunophenotyping and minimal residual disease detection.
- High-Throughput Analytics: Supports the management of large sample volumes, ensuring operational efficiency.
- Exceptional Sensitivity: Critical for obtaining accurate results in clinical diagnostics.

Services:

Cytek Biosciences enhances the value of its products through comprehensive services designed to ensure that customers can maximize the potential of their flow cytometry systems:

1. Training and Technical Support:
- The company offers both virtual and in-person training sessions, ensuring users can effectively operate their systems.
- Services include:
- Installation Training: Assisting users in setting up their systems optimally.
- Planned Maintenance: Scheduling routine check-ups to maintain system performance.
- Calibration Services: Ensuring that equipment operates within specified parameters to produce accurate results.

2. Research Services:
- Cytek provides a spectrum of research services, including:
- Contract Research Services: Collaborating with customers on specific research projects to alleviate workload.
- Assay Development Services: Tailoring assays to meet unique research requirements.
- Custom Conjugation Services: Allowing researchers to customize flow cytometer reagents to suit specific experimental needs.
- The company employs a team of experts who assist customers with:
- Protocol Optimization: Refining methodologies to enhance experimental outcomes.
- Data Analysis Support: Providing guidance on interpreting complex flow cytometry data.

Through its well-defined segments, advanced product offerings, and robust service portfolio, Cytek Biosciences Inc. positions itself as a vital partner for scientists and clinical researchers aiming to further their studies and improve clinical outcomes.


Composition of Cytek Biosciences Inc Revenues by Segments

 
Academia and government    39.16 % of total Revenue
Biotechnology pharmaceutical distributor and contract research organizations    62.88 % of total Revenue
Direct sales channel    69.98 % of total Revenue
Distributor channel    32.06 % of total Revenue
United States    56.38 % of total Revenue
China    8.32 % of total Revenue
Reportable Segment    102.04 % of total Revenue
Product    66.53 % of total Revenue
Product Reportable Segment    66.53 % of total Revenue
Service    35.5 % of total Revenue
Service Reportable Segment    35.5 % of total Revenue
EMEA    24.89 % of total Revenue
APAC    17.92 % of total Revenue
Other    2.85 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Academia and government 16.94 39.16 %
Biotechnology pharmaceutical distributor and contract research organizations 27.20 62.88 %
Direct sales channel 30.27 69.98 %
Distributor channel 13.87 32.06 %
United States 24.39 56.38 %
China 3.60 8.32 %
Reportable Segment 44.14 102.04 %
Product 28.78 66.53 %
Product Reportable Segment 28.78 66.53 %
Service 15.36 35.5 %
Service Reportable Segment 15.36 35.5 %
EMEA 10.77 24.89 %
APAC 7.75 17.92 %
Other 1.23 2.85 %
Total 43.25 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Academia and government -1.13 % -
Biotechnology pharmaceutical distributor and contract research organizations 11.8 % -
Direct sales channel 1 % -
Distributor channel 20.71 % -
United States 31.57 % -
China -32.08 % -
Reportable Segment 6.46 % -
Product 2.38 % -
Product Reportable Segment 2.38 % -
Service 15.05 % -
Service Reportable Segment 15.05 % -
EMEA -6.93 % -
APAC -12.82 % -
Other -50.02 % -
Total 5.1 % -78.53 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Reportable Segment -18.87 -
Total -1.49 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Reportable Segment - -
Total - -




Annual Report on Cytek Biosciences Inc Divisions, Sales by Country

 
Academia and government   Academia and government Segment contribution to total sales 42.07 % of total Revenue
Biotechnology pharmaceutical distributor and contract research organizations   Biotechnology pharmaceutical distributor and contract research organizations Segment contribution to total sales 57.94 % of total Revenue
Direct sales channel   Direct sales channel Segment contribution to total sales 72.8 % of total Revenue
Distributor channel   Distributor channel Segment contribution to total sales 27.21 % of total Revenue
United States   United States Segment contribution to total sales 47.28 % of total Revenue
China   China Segment contribution to total sales 10.18 % of total Revenue
Reportable Segment   Reportable Segment Segment contribution to total sales 100.02 % of total Revenue
Product   Product Segment contribution to total sales 71.59 % of total Revenue
Product Reportable Segment   Product Reportable Segment Segment contribution to total sales 71.59 % of total Revenue
Service   Service Segment contribution to total sales 28.42 % of total Revenue
Service Reportable Segment   Service Reportable Segment Segment contribution to total sales 28.42 % of total Revenue
EMEA   EMEA Segment contribution to total sales 27.74 % of total Revenue
APAC   APAC Segment contribution to total sales 20.39 % of total Revenue
Other   Other Segment contribution to total sales 4.61 % of total Revenue


Twelve months ended 2025
CTKB s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Academia and government 84.76 42.07 %
Biotechnology pharmaceutical distributor and contract research organizations 116.73 57.94 %
Direct sales channel 146.67 72.8 %
Distributor channel 54.83 27.21 %
United States 95.25 47.28 %
China 20.50 10.18 %
Reportable Segment 201.49 100.02 %
Product 144.23 71.59 %
Product Reportable Segment 144.23 71.59 %
Service 57.26 28.42 %
Service Reportable Segment 57.26 28.42 %
EMEA 55.88 27.74 %
APAC 41.08 20.39 %
Other 9.28 4.61 %
Total 201.46 100 %


Twelve months ended 2025
CTKB s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Reportable Segment -66.54 -
Total -66.54 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Academia and government 4.76 % -
Biotechnology pharmaceutical distributor and contract research organizations -2.35 % -
Direct sales channel -2.14 % -
Distributor channel 8.39 % -
United States 2.85 % -
Reportable Segment 0.52 % -
Product -5.89 % -
Product Reportable Segment -5.89 % -
Service 21.34 % -
Service Reportable Segment 21.34 % -
EMEA -10.36 % -
APAC 14.84 % -
Other -4.64 % -
Total 0.68 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.